Director, Solid Tumor Cell Therapy Program

NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, with some of the lowest mortality rates in the nation. According to U.S. News & World Report, NYU Langone Health has more No. 1‑ranked specialties than any other medical center in the U.S. It is named on the USNWR Honor Roll of the top 20 hospitals in the nation and among the No. 1 hospitals in the New York area. NYULH offers a comprehensive range of medical services across 5 inpatient locations, the Perlmutter Cancer Center (ranked among the top 20 cancer centers nationally), and more than 320 outpatient locations in New York and Florida. The system includes two tuition‑free medical schools and a vast research enterprise. The Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (PCC)—an NCI‑designated Comprehensive Cancer Center—is on a substantial growth trajectory, operating 11 clinical locations across Manhattan, Brooklyn, Queens and Long Island, and a growing clinical‑trials program.

About the role

The Director of the Solid Tumor Cell Therapy Program will lead the expansion of novel solid‑tumor immunotherapy approaches. The role requires effective interaction with colleagues across disease subtypes and disciplines. Experience or focus in any relevant solid‑tumor subtype is welcomed.